Learn how you can get involved to support a nearby RSV vaccine study for older adults.
Provide your contact information in the “Sign Up Here” tab or below and a member of the Effectus team will reach out with program details. Should you have any questions prior, please call us directly at 703-635-8975.
About the Research Study
GlaxoSmithKline is currently conducting a phase 3, observer-blind, randomized, placebo-controlled study called RSV OA=ADJ-018. The study is researching the immune response and safety of a new investigational vaccine (RSV-OA vaccine) for respiratory syncytial virus (RSV) for older adults, with or without underlying chronic diseases.
Who Can Enroll Into the Study?
Approximately 1520 people from several countries will take part in this study, 380 in the US. It will be conducted in the following groups of participants:
• Adults (50-59 years of age) with chronic lung or heart disease, diabetes mellitus type 1 or 2, or chronic kidney or liver disease
• Healthy adults (50-59 years of age)
• Older adults (60 years of age or above)
All older adults will receive the investigational RSV-OA vaccine. In the age group 50-59 years of age, participants have 2 out of 3 chances to receive the investigational RSV-OA vaccine and 1 in 3 chance to receive placebo.
How You Can Get Involved
As a health care provider (HCP) who manages these patient populations, you are invited to participate in the Effectus Patient Identification and Consultation Program to help identify candidates for the RSV OA=ADJ-018 Study. Should you decide to participate, you would identify which of your adult patients meet the provided inclusion/exclusion criteria and discuss the opportunity with them to participate at the nearby study site. At the study site, patients will undergo formal study screening to determine eligibility.
Compensation at fair market value will be available for HCPs who participate and meet program requirements.
The Effectus Patient Identification and Consultation Program
Effectus Patient Identification and Consultation Program Overview
Support Provided
Effectus will be your trusted partner throughout your participation, helping to facilitate your patients to the study site and thus relieving the burden on your practice. If you wish to participate, you will be asked to review and sign a Services Agreement with Effectus, which outlines your program responsibilities and compensation. Participation is completely voluntary, and you can opt out at any time. Background on the study, program materials, and program logistics will be reviewed in detail during a 1-hour virtual training session.
Why Participate?
The RSV OA=ADJ-018 Study provides an opportunity to contribute to the research and advancement of a potential RSV vaccine for adults.
Sign a services
agreement.
Receive a package of
program materials and
complete a simple, one-hour
virtual training session.
Utilize key screening
criteria to identify
potentially eligible
patients.
If the patient meets the criteria,
conduct a neutral consultation
about the availability of the
nearby study and gauge the
patient’s interest.
If the patient is interested in
participation, our team of dedicated
Patient Facilitators help ensure a
smooth patient transfer from your
office to the study.
The patient is scheduled
and presents at the study
site for the screening
appointment.
The patient’s enrollment
status is determined and is
relayed back to the treating
HCP by Effectus.
For more information on our program, please visit https://www.effectusctr.com/physician-network/.
The Effectus Patient Identification and Consultation Program
Contact Us
Montana Markell, Project Coordinator
Phone: 703-635-8975
Email: mmarkell@effectusctr.com